Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: Methodological pitfalls and clinical relevance

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 1, 2009, Pages 1-11

  Nezos, Adrianos ^a   Lembessis, Peter ^a,b   Sourla, Antigone ^a,b   Pissimissis, Nikolaos ^a   Gogas, Helen ^c   Koutsilieris, Michael ^a,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b Endo/Oncoresearch Laboratory   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Circulating melanoma cells; Clinical significance; Molecular markers

Indexed keywords

CD146 ANTIGEN; MOLECULAR MARKER; PROTEIN P97; RNA; TUMOR ANTIGEN; TUMOR MARKER;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LYMPH NODE BIOPSY; MELANOCYTE; MELANOMA CELL; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA DEGRADATION;

ANTIGENS, NEOPLASM; HUMANS; MELANOMA; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149215865     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.009     Document Type: Review

References (109)

1. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consensus-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007;17:393-9.
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51-65.
3. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma [review]. J Cell Mol Med 2007;11:1052-68.
4. Melanoma techniques and protocols. In: Nickoloff BJ, editor. Methods in molecular medicine, vol 61. Totowa, NJ: Humana Press Inc., 2001:3-8.
5. Goldstein BG, Goldstein AO. Diagnosis and management of malignant melanoma. Am Fam Physician 2001;63:1359-68, 1374.
6. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622-34.
7. Garbe C, Ellwanger U, Tronnier M, Brocker EB, Orfanos CE. The New American Joint Committee on Cancer Staging System for Cutaneous Melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer 2002;94:2305-7.
8. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma: prognostic classification of anatomic location. Cancer 1995;75:2492-8.
9. Rivers JK. Is there more than one road to melanoma? Lancet 2004;363:728-30.
10. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 2001;158:78-92.
11. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849-57.
12. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardò T, Fierro MT, et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res 2007;17:75-82.
13. Davids V, Kidson SH, Hanekom GS. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate. Mol Pathol 2003;56:43-51.
14. Kuo CT, Hoon DS, Takeuchi H, Turner R, Wang HJ, Morton DL, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003;21:3566-72.
15. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents, vol VIII. Lyon, France: IARC Press, 2003.
16. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects [review]. Expert Rev Proteomics 2007;4:741-56.
17. Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells [review]. Pigment Cell Res 2007;20:80-91.
18. Szenajch J, Jasinski B, Synowiec A, Kulik J, Chomicka M, Struzyna J, et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin Chem 2003;49:1450-7.
19. Martinez SR, Hoon DS. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony? [review] J Cell Biochem 2005;96:473-83.
20. Mitropapas G, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin Chem Lab Med 2006;44:1403-9.
21. de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer 1999;80:883-91.
22. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
23. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000;60:2253-7.
24. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007;53:1206-15.
25. Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 2005;15:409-16.
26. Voit C, Kron M, Rademaker J, Schwürzer-Voit M, Sterry W, Weber L, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005;23:1218-27.
27. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998;16:1760-9.
28. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quintó L, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002;20:4032-9.
29. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003;89:1457-62.
30. Visús C, Andres R, Mayordomo JI, Martinez-Lorenzo MJ, Murillo L, Sáez-Gutiérrez B, et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res 2007;17:83-9.
31. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res 2004;14:S17-9.
32. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007;21:752-9.
33. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001;137:325-30.
34. Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J, et al. Molecular diagnostics in melanoma [review]. J Am Acad Dermatol 2005;52:743-75; 775-8 [quiz].
35. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol 2008;22:56-64.
36. Dutcher JP. The prognostic role of detection of circulating melanoma cells in the blood. J Clin Oncol 2003;21:757-9.
37. Blake JA, Ziman MR. Pax3 transcripts in melanoblast development. Dev Growth Differ 2005;47:627-35.
38. Matsuzaki Y, Hashimoto S, Fujita T, Suzuki T, Sakurai T, Matsushima K, et al. Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J Immunother 2005;28:10-9.
39. Vachtenheim J, Novotná H. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol (Noisy-le-grand) 1999;45:1075-82.
40. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005;51:981-8.
41. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22:2671-80.
42. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A, et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res 2000;10:355-62.
43. Itakura E, Huang RR, Wen DR, Paul E, Wünsch PH, Cochran AJ. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi. Mod Pathol 2008;21:326-33.
44. Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, et al. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 2000;19:395-402.
45. Theos AC, Truschel ST, Raposo G, Marks MS. The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function [review]. Pigment Cell Res 2005;18:322-36.
46. Kushimoto T, Valencia JC, Costin GE, Toyofuku K, Watabe H, Yasumoto K, et al. The Seiji memorial lecture: the melanosome: an ideal model to study cellular differentiation. Pigment Cell Res 2003;16:237-44.
47. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 2003;163:333-43.
48. Tsukamoto K, Ueda M, Hirata S, Osada A, Kitamura R, Takahashi T, et al. gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients. J Dermatol Sci 2000;23:126-31.
49. Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004;10:1605-12.
50. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-9.
51. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
52. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006;20:3426-39.
53. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40.
54. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006;12:1137-43.
55. Samija I, Lukac J, Maric-Brozic J, Kusic Z. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croat Med J 2004;45:142-8.
56. Lin L, Gerth AJ, Peng SL. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J Exp Med 2004;200:115-22.
57. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12:406-14.
58. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007;13:6344-50.
59. Murakami M, Iwata Y, Funaba M. Expression and transcriptional activity of alternative splice variants of Mitf exon 6. Mol Cell Biochem 2007;303:251-7.
60. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997;57:1371-6.
61. Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction [review]. J Clin Oncol 2003;21:767-73; J Clin Oncol 2003;21:2048 [erratum].
62. Enk CD, Lotem M, Gimon Z, Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res 2004;14:361-5.
63. Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003;9:1497-502.
64. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005;23:8057-64.
65. Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004;111:741-5.
66. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999;17:2562-71.
67. Schmidt H, Sorensen BS, Sjoegren P, Christensen IJ, Fode K, Larsen J, et al. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. J Invest Dermatol 2006;126:849-54.
68. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 1990;110:1227-37.
69. Kulik J, Nowecki ZI, Rutkowski P, Ruka W, Rochowska M, Skurzak H, et al. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Res 2001;11:65-73.
70. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
71. Bosserhoff AK, Echtenacher B, Hein R, Buettner R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res 2001;11:417-21.
72. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149-53.
73. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891-6.
74. Gradilone A, Ribuffo D, Silvestri I, Cigna E, Gazzaniga P, Nofroni I, et al. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance. Ann Surg Oncol 2004;11:983-7.
75. de Vries TJ, Fourkour A, Punt CJ, Diepstra H, Ruiter DJ, van Muijen GN. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood. Br J Cancer 1999;81:1066-70.
76. Sugita Y, Fujiwara Y, Hoon DS, Miyamoto A, Sakon M, Kuo CT, et al. Overexpression of beta 1,4N-acetylgalactosaminyl-transferase mRNA as a molecular marker for various types of cancers. Oncology 2002;62:149-56.
77. Giacomini P, Natali P, Ferrone S. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol 1985;135:696-702.
78. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms [review]. Ann NY Acad Sci 2004;1028:340-50.
79. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 2005;125:526-31.
80. Schittek B, Blaheta HJ, Ellwanger U, Garbe C. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients [review]. Recent Results Cancer Res 2001;158:93-104.
81. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 2008;215:287-91.
82. Miyashiro I, Kuo C, Huynh K, Iida A, Morton D, Bilchik A, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001;47:505-12.
83. Goydos JS, Patel M, Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 2001;98:76-80.
84. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21:495-505.
85. Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 2007;45:1488-94.
86. Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers [review]. Trends Mol Med 2006;12:130-9.
87. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy [review]. Nat Rev Cancer 2007;7:834-46.
88. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008;21:39-55.
89. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
90. Pantel K, Alix-Panabières C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 2007;4:62-3.
91. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node [review]. Mod Pathol 2006;19(Suppl 2):S71-87.
92. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-9.
93. Steen S, Nemunaitis J, Fisher T, Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc (Bayl Univ Med Cent) 2008;21:127-32.
94. Prichard RS, Dijkstra B, McDermott EW, Hill AD, O'Higgins NJ. The role of molecular staging in malignant melanoma [review]. Eur J Surg Oncol 2003;29:306-14.
95. Santonocito C, Concolino P, Lavieri MM, Ameglio F, Gentileschi S, Capizzi R, et al. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. Clin Chim Acta 2005;362:85-93.
96. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-7.
97. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999;5:1843-8.
98. Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003;21:2558-63.
99. Palmieri G, Satriano SM, Budroni M, Cossu A, Tanda F, Canzanella S, et al. Serial detection of circulating tumour cells by reverse transcriptase- polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006;6:266.
100. Fidler IJ. Critical factors in the biology of human cancer metastasis: 28th GHA Clowes memorial award lecture. Cancer Res 1990;50:6130-8.
101. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
102. Koutsilieris M, Lembessis P, Luu-The V, Sourla A. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis 1999;17:823-30.
103. Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 1998;34:750-3.
104. Keilholz U (for the EORTC Melanoma Cooperative Group). Diagnostic PCR in melanoma: methods and quality assurance. Eur J Cancer 1996;32A:1661-3.
105. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma [review]. Recent Results Cancer Res 2001;158:78-92.
106. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
107. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19:290-302.
108. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005;11:7234-42.
109. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008;27:565-73.